BeyondSpring’s Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium on Medical Oncology and 7th Annual Meeti...
BeyondSpring, Inc. - Ordinary Shares (BYSI)
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.beyondspringpharma.com
Company Research
Source: GlobeNewswire
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, announced today that Dr. Yuankai Shi presented positive data from the Phase 2 portion of Study 105, a prospective Phase 2/3 trial of Plinabulin, its lead candidate, for the prevention of chemotherapy-induced neutropenia (CIN), in a keynote presentation at the 12th Annual Chinese Symposium on Medical Oncology (CSMO) and the 7th Annual Meeting of the Chinese Association for Clinical Oncologists (CACO) on Saturday, June 23, 2018, at the Radegast Lake View Hotel in Beijing. Dr. Shi is the Principal Investigator in China for BeyondSpring’s Studies 105 and 106 for the prevention of CIN, as well as the Co-Principal Investigator in China for Study 103 for the treatment of advanced non-small cell lung cancer (NSCLC). “In clinical studies to date, Plinabulin has demonstrated dual functions: First, in mai
Show less
Read more
Impact Snapshot
Event Time:
BYSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BYSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BYSI alerts
High impacting BeyondSpring, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
BYSI
News
- BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung CancerGlobeNewswire
- Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?PR Newswire
- Retail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewarded [Yahoo! Finance]Yahoo! Finance
- BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing RequirementsGlobeNewswire
BYSI
Sec Filings
- 3/18/24 - Form 6-K
- 2/26/24 - Form 6-K
- 2/14/24 - Form SC
- BYSI's page on the SEC website